CDC25A and breast carcinoma: FYN is also highly expressed in tamoxifen-resistant estrogen receptor-positive (ER+) breast cancer cell lines mainly because it plays an important role in the activation of important cell-cycle-associated proteins such as 14-3-3 and Cdc25A, ultimately contributing to overcoming the antiproliferative effects of tamoxifen17,24.